2Yuen MF,Lai CL. Serological markers of liver cancer[J]. Best Pract Res Clin Gastroenterol, 2005,19 (3) : 91-99.
3陶义训.免疫学和免疫学检验[M].2版.北京:人民卫生出版社,1996:59.
4Downer S, Joel A, Allbrighy A, et al. Adouble blind placebo controlled trial of medroxyprogestrone acetate ( MPA ) in advanced lung cancer.Nethedand Oncol, 1991, 13 ( 1 ) :75 - 79.
5Belier E, Tattersall M, Lumley T, et al. Improve quality of life with megestrol acetate in patients with endocrine in sensitive advanced cancer.Ann Oncol, 1997, 8(3):277 -283.
6Pannuti F, Cstrocchi E. Hight doses of MPA in oncology problems,doubts and certainties. Semin Oncol, 1998, 1(Suppll):76 - 78.
7Wils JA. Myelopretective effect of high dose. MPA Chemotherapia.1988, 7(1):60-62.
8Lelli G, Angekelli B, Giambiasi ME, et al. The anabokic effect of high dose medroxyprogesterone acetate in oncologh. Pharmacol Res Commun,1983, 15(6) :561 - 568.
